CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Parkinson’s Institute |
R. Jeremy Nichols |
Basic Biology III |
Understanding the role of LRRK2 in iPSC cell models of Parkinson’s Disease |
$1,482,822 |
| Scripps Research Institute |
Dr. Kristin K Baldwin Dr. |
Basic Biology III |
Identifying sources of mutation in human induced pluripotent stem cells by whole genome sequencing |
$1,705,500 |
| University of California, Berkeley |
Dr. Michael P. Rapé Dr. |
Basic Biology III |
Ubiquitin-dependent control of hESC self-renewal and expansion |
$1,224,805 |
| University of California, Los Angeles |
Dr. Gay Miriam Crooks |
Basic Biology III |
Forming the Hematopoietic Niche from Human Pluripotent Stem Cells |
$1,252,857 |
| University of California, San Diego |
Dr. Charles C. King Dr. |
Basic Biology III |
Biological relevance of microRNAs in hESC differentiation to endocrine pancreas |
$1,313,649 |
| University of California, Berkeley |
Dr. Song Li |
Basic Biology III |
Induced Pluripotent Stem Cells for Tissue Regeneration |
$1,209,148 |
| University of California, San Diego |
Karl H. Willert |
Tools and Technologies II |
Homologous recombination in human pluripotent stem cells using adeno-associated virus. |
$1,659,043 |
| Stanford University |
Dr. Marius Wernig MD, PhD |
Tools and Technologies II |
Cellular tools to study brain diseases affecting synaptic transmission |
$1,664,382 |
| Stanford University |
Professor Irving L Weissman MD |
Tools and Technologies II |
Antibody tools to deplete or isolate teratogenic, cardiac, and blood stem cells from hESCs |
$1,463,814 |
| TriFoil Imaging, Inc. |
Dr. Joann Zhang |
Tools and Technologies II |
Tri-resolution Visualization System for Stem Cells and Tissue Regeneration Monitoring |
$1,456,989 |
| Cedars-Sinai Medical Center |
Professor Clive Niels Svendsen |
Tools and Technologies II |
Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. |
$1,933,022 |
| University of California, Berkeley |
Dr. David V. Schaffer |
Tools and Technologies II |
Engineering Defined and Scaleable Systems for Dopaminergic Neuron Differentiation of hPSCs |
$1,340,816 |
| Stanford University |
Dr. Brian K. Rutt |
Tools and Technologies II |
Development of Single Cell MRI Technology using Genetically-Encoded Iron-Based Reporters |
$1,833,348 |
| Parkinson’s Institute |
Dr. Birgitt Schuele |
Tools and Technologies II |
Editing of Parkinson’s disease mutation in patient-derived iPSCs by zinc-finger nucleases |
$1,327,983 |
| University of California, San Francisco |
Dr Daniel A. Lim MD, PHD |
Tools and Technologies II |
Development and preclinical testing of new devices for cell transplantation to the brain. |
$1,795,891 |
| GMR Epigenetics |
Dr. Jifan Hu |
Tools and Technologies II |
Robust generation of induced pluripotent stem cells by a potent set of engineered factors |
$1,356,052 |
| Stanford University |
Dr. Sarah C Heilshorn |
Tools and Technologies II |
Preparation and Delivery of Clinically Relevant Numbers of Stem Cells Using 3D Hydrogels |
$600,695 |
| University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Tools and Technologies II |
Developing a method for rapid identification of high-quality disease specific hIPSC lines |
$1,686,069 |
| University of California, Los Angeles |
Dr. Richard A. Gatti |
Tools and Technologies II |
Use of hiPSCs to develop lead compounds for the treatment of genetic diseases |
$1,833,054 |
| Stanford University |
Dr. Theo D. Palmer PhD |
Tools and Technologies II |
Development of small molecule screens for autism using patient-derived iPS cells |
$1,797,606 |
| University of California, Berkeley |
Dr. Steven M. Conolly |
Tools and Technologies II |
Magnetic Particle Imaging: A Novel Ultra-sensitive Imaging Scanner for Tracking Stem Cells In Vivo |
$1,311,596 |
| University of California, San Diego |
Shu Chien |
Tools and Technologies II |
Development of Synthetic Microenvironments for Stem Cell Growth and Differentiation |
$1,706,628 |
| University of California, Los Angeles |
Dr. Thomas Carmichael M.D., Ph.D. |
Tools and Technologies II |
Development of a Hydrogel Matrix for Stem Cell Growth and Neural Repair after Stroke |
$1,825,613 |
| Stanford University |
Dr. Michele Calos |
Tools and Technologies II |
Site-specific integration of Lmx1a, FoxA2, & Otx2 to optimize dopaminergic differentiation |
$1,592,897 |
| Fluidigm Corporation |
Dr. Marc A Unger |
Tools and Technologies II |
Development and Application of Versatile, Automated, Microfluidic Cell Culture System |
$1,939,236 |
| University of California, Los Angeles |
Dr. Martin Gabriel Martin |
Tools and Technologies II |
Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders |
$1,783,250 |
| University of California, Los Angeles |
Dr. Sophie X Deng |
Early Translational II |
Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$697,507 |
| University of California, San Francisco |
Dr. Arturo Alvarez-Buylla |
Early Translational II |
Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy |
$1,564,016 |
| University of California, Davis |
Dr. Mark Zern |
Early Translational II |
Liver Cell Transplantation |
$4,212,621 |
| Stanford University |
Dr. Michele Calos |
Early Translational II |
Stem Cell Therapy for Duchenne Muscular Dystrophy |
$2,267,261 |
| University of California, Irvine |
Dr. Brian J. Cummings |
Early Translational II |
Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury |
$1,517,767 |
| University of California, Los Angeles |
Dr. Sophie X Deng |
Early Translational II |
Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$1,524,947 |
| Cedars-Sinai Medical Center |
Dr. Dan Gazit |
Early Translational II |
Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures |
$1,927,698 |
| University of California, Los Angeles |
Leif Havton |
Early Translational II |
Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons |
$75,628 |
| University of California, Irvine |
Leif A Havton |
Early Translational II |
Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons |
$1,527,011 |
| City of Hope, Beckman Research Institute |
Dr. Yanhong Shi Ph.D. |
Early Translational II |
Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell |
$1,835,983 |
| City of Hope, Beckman Research Institute |
Dr. David Louis DiGiusto |
Early Translational II |
Development of RNA-based approaches to stem cell gene therapy for HIV |
$3,097,160 |
| University of California, Davis |
Dr. Roslyn Rivkah Isseroff |
Early Translational II |
Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds |
$4,629,747 |
| University of California, Los Angeles |
Dr. Noriyuki Kasahara |
Early Translational II |
Stem cell-based carriers for RCR vector delivery to glioblastoma |
$3,340,625 |
| Salk Institute for Biological Studies |
Dr. Fred H Gage |
Early Translational II |
Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model |
$2,472,839 |
| University of California, Irvine |
Dr. Henry John Klassen |
Early Translational II |
Human retinal progenitor cells as candidate therapy for retinitis pigmentosa |
$1,803,768 |
| Children’s Hospital of Los Angeles |
Dr. Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$850,769 |
| University of California, San Francisco |
Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$2,756,536 |
| Buck Institute for Age Research |
Dr. Xianmin Zeng |
Early Translational II |
Banking transplant ready dopaminergic neurons using a scalable process |
$4,983,013 |
| iPierian, Inc. |
Dr. John Dimos |
Early Translational II |
New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells |
$2,410,000 |
| University of California, Los Angeles |
Prof. Bruno Peault |
Early Translational II |
Harnessing native fat-residing stem cells for bone regeneration |
$5,359,076 |
| Scripps Research Institute |
Peter G. Schultz |
Early Translational II |
Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis |
$6,047,249 |
| University of California, San Diego |
Professor Alysson R Muotri |
Early Translational II |
Developing a drug-screening system for Autism Spectrum Disorders using human neurons |
$1,376,198 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Early Translational II |
A hESc-based Development Candidate for Huntington’s Disease |
$3,955,038 |
| University of California, San Diego |
Catriona Jamieson |
Early Translational II |
Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy |
$3,103,041 |
